Navigation Links
Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions

PLYMOUTH MEETING, Pa., June 19, 2007 /PRNewswire-FirstCall/ -- Genaera Corporation today announced that it will present a poster on trodusquemine (MSI-1436), its novel anti-obesity compound, during the American Diabetes Association (ADA) 67th Scientific Sessions, June 22 to 25 in Chicago.

The abstract, # 1801-P, is titled, "Trodusquemine is a Multiple Pathway Inhibitor that Causes Differential Weight Loss, Reduces Adiposity, and Improves Plasma Insulin and Leptin Levels."

The poster will be available from Saturday, June 23 through Monday, June 25 during the times the General Poster Session is open to conference attendees. Representatives from Genaera will be available to discuss the poster on Sunday, June 24 from 6:15 p.m. to 7:30 p.m. (CT) and on Monday, June 25 from 12:00 p.m. to 2:00 p.m. (CT).

For more information online, please visit: http://scientificsessions.diabetes.org/index.cfm?fuseaction=Custom.Content&Men uID=1000

About Trodusquemine (MSI-1436)

Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP-1B is central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metaboli
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

Post Your Comments:
(Date:11/24/2009)...irstCall/--NeurocrineBiosciences,Inc.(Nasdaq: NBIX...xecutiveOfficerofNeurocrineBiosciences,willbeprese...ceinNewYork. ,, ThelivepresentationtakesplaceTu...p.m.PacificTime(PT).Thepresentationwillbesimultane...t http://www.neurocrine.com . ,, Ifyouareunable...
(Date:11/24/2009)...e-FirstCall/--ZimmerHoldings,Inc.(NYSE: ZMH ;SIX:Z...ualPiperJaffrayHealthCareConferenceinNewYork,NewYo...livewebcastofthepresentationcanbeaccessedviaZimmer...r.com .Thewebcastwillbearchivedforreplayfollowingt...din1927andheadquarteredinWarsaw,Indiana,Zimmerdesi...
(Date:11/24/2009)...4/PRNewswire/--VisageImaging®,Inc.,awhollyown...ucingVisage®7,thecompany,snewgenerationdiagno...diologicSocietyofNorthAmerica(RSNA),November29toDe...ersnewlevelsofversatilityandperformancetoradiologi...icians.TheVisage7UniversalViewerisasinglethinclien...
Breaking Medicine Technology:Visage Imaging Introduces Visage(R) 7 for Windows and Mac OS X 2Gerresheimer Sells Technical Plastics Business 12861 1Gerresheimer Sells Technical Plastics Business 12861 2A young brain for an old bee 9076 1A young brain for an old bee 9076 2FDA Panel Urges Ban on Vicodin Percocet 50476 1FDA Panel Urges Ban on Vicodin Percocet 50476 2FDA Panel Urges Ban on Vicodin Percocet 50476 3FDA Panel Urges Ban on Vicodin Percocet 50476 4
...lif., June 4 TorreyPines,Therapeutics, Inc. (Nasd...nical trial to evaluate the analgesic effect of NG...te, tezampanel., The randomized, double-blind, pl...thy volunteers at a single center in the United St...nd,s safety and tolerability and to,assess the tim...
...ports Positive Top-line Results from Second Phase ...) -, PT. RICHMOND, Calif., June 4 Transcept Phar...ny deriving significant new patient,benefits from ...leted all,pivotal and supporting clinical trials t...NDA) for its lead product candidate, Intermezzo(R)...
Other Medicine Technology:TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel 2TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel 3Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008 2Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008 3
(Date:11/24/2009)...c.todayannouncedtheacquisitionofRetirementCapitalG...sationandbenefitplanprovidersheadquarteredinSanDie...waukee,Boston,ChicagoandAtlanta.RCGwasfoundedin200...enefitsindustry. ,, "Weareexcitedtoannouncethea...sence,"statesBillPollock,ChairmanandFounderofNIP."...
(Date:11/24/2009)...re/--Dr.NelsonEscobar,aphysicianwiththeMarianjoyMe...Award.TheawardwaspresentedtohimbytheBrainInjuryAss...onOctober30,2009. ,, AccordingtotheBIAofIllinoi...rtiseinaddressingthecomplexneedsofpersonswithbrain...reofhispatientsandtheirfamiliesastheyrebuildtheirl...
(Date:11/24/2009)...CenteneCorporation(NYSE: CNC )todayannouncedthatth...oneoftwoCoordinatedCareOrganizationstoparticipatei...iCAN),acoordinatedcareprogramforMississippiMedicai...ecuteacontractinwhichthecompanywillserveeligibleme...lia). ,, BasedinJackson,Miss.,Magnoliawillworkw...
(Date:11/24/2009)...etween high- and low-volume centers, study found ,...Do hospitals that conduct the most angioplasties n...Maybe not. , Prior research had suggested that ...pening procedures, but a new study involving over ...ls performing more or less equally. , The study...
(Date:11/24/2009)... use but higher costs , , TUESDAY, Nov. ... may contribute to higher Medicaid costs, accordin... used antiplatelet drug clopidogrel (Plavix). ,...te Medicaid programs found that direct-to-consumer...le,s use of the drug but appeared to be associated...
Breaking Medicine News(10 mins):Health News:NIP Acquires San Diego Executive Benefits Firm 2Health News:Marianjoy Medical Group Physician Receives James Brady Award 2Health News:Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3Health News:Advertising to Consumers May Raise Drug Prices 2
..., Feb. 12 Affirming its commitment,to preventing ...onal,Lieutenant Governors Association Executive Co...n John R. Elliott HERO Campaign for Designated Dri...ng.,It was established by the family of Navy Ensig...
... MONICA, Calif., Feb. 12 A consumer,group today r...nathan,Gruber supporting mandatory purchase of pri... that most Americans are "over-insured" and to,def...rwatchdog.org/resources/MandatoryInsuranceCritique...
...ing quickly mutating noroviruses might mean yearly...HealthDay News) -- It may be possible to develop a...of stomach flu -- but it,s likely a such a vaccine...nfect cells after attaching to histo-blood group a...
...Feb. 12 PSI, a leading provider of child,support ...nced today the,signing of a contract with the Ohio...continue delivering new hire reporting services fo...r extensions., Key responsibilities under the con...
...oard aimed at reducing cross contaminations includ... MRSA, JACKSONVILLE, Fla., Feb. 12 Seal Shield L...LVER SEAL(TM) Washable, Antimicrobial,Keyboard. Ac...from SILVER SEAL(TM) Antimicrobial plastic. The SI...
...ON, Fla., Feb. 12 The Generic Pharmaceutical,Asso...members of its newly,elected Executive Committee a...nt and CEO of Teva North America, to serve as its ... top 20,pharmaceutical companies in the world and ...
Other Medicine News:Health News:National Lt. Governors Association Endorses HERO Campaign; 1st National Association of State Elected Officials Supporting Grassroots Designated Driving Program 2Health News:Consumer Group Finds Use of Outdated Data and Other Major Flaws in Economist's Defense of Mandatory Purchase of Private Health Insurance 2Health News:Vaccine Could Cut Bouts With Stomach Flu 2Health News:Ohio Selects Policy Studies Inc. (PSI) to Continue Operating Its New Hire Reporting Program 2Health News:Seal Shield Ships New SILVER SEAL(TM) Washable, Antimicrobial Keyboard 2Health News:GPhA Announces 2008-2009 Executive Committee; Teva North America's Bill Marth Elected as Chairman of the Board 2
...c assist system primarily designed as a permanent ...ering heart failure., ,It is a blood pump that...art to help the ailing hearts pumping function and... ,It can also be used as a bridge to heart trans...
Captia™ Varicella-Zoster Virus IgM
...oster Virus (VZV) IgG Enzyme- linked Immunosorbent...uantitative determination of IgG antibody to VZV i...ed for the determination of immune status. Paired ...strate seroconversion or a significant rise in ant...
Varicella-Zoster Virus IgM
Medicine Products: